Attorney Docket No. ATTE-002/02US **PATENT**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on March 30, 2004.

By: Cathi L.G. Thoorsell
Cathi L.G. Thoorsell

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of Amy L. ALLAN *et al.*

Serial No.:	10/723,144	Examiner:	Not yet assigned
Confirmation No.:	9257	Art Unit:	1641
Filed:	November 25, 2003		

For: **PEPTIDES WHICH INHIBIT ANGIOGENESIS, CELL MIGRATION, CELL INVASION AND CELL PROLIFERATION, COMPOSITIONS AND USES THEREOF**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT TRANSMITTAL

Enclosed is an Information Disclosure Statement and accompanying Form PTO/SB/08A for the above-identified patent application. In accordance with 37 C.F.R. §1.97(b), no additional fee for submission of the IDS is required. A return receipt postcard is also enclosed.

The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R. §§1.16, 1.17, and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 03-3117.

Dated: March 30, 2004

Respectfully submitted,
COOLEY GODWARD LLP

By: Sunil K. Singh
Sunil K. Singh
Reg. No. 45,298

Cooley Godward LLP
ATTN: Patent Group
Five Palo Alto Square
3000 El Camino Real
Palo Alto, CA 94306-2155
Tel: (650) 843-5000 Fax: (650) 857-0663
672763 v1/PA

Attorney Docket No. ATTE-002/02US **PATENT**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on March 30, 2004.

By: Cathi L.G. Thoorsell
Cathi L.G. Thoorsell

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of Amy L. ALLAN *et al.*

Serial No.: 10/723,144 Examiner: Not yet assigned

Confirmation No.: 9257 Art Unit: 1641

Filed: November 25, 2003

For: **PEPTIDES WHICH INHIBIT ANGIOGENESIS, CELL MIGRATION, CELL INVASION AND CELL PROLIFERATION, COMPOSITIONS AND USES THEREOF**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97(b)

In accordance with the duty of disclosure set forth in 37 C.F.R. §1.56, Applicant(s) hereby submits the following information in conformance with 37 C.F.R. §§1.97 and 1.98. Pursuant to 37 C.F.R. §1.98, a copy of each document cited in the attached Form PTO/SB/08 is enclosed. This Information Disclosure Statement is filed before the mailing date of a first office action on the merits.

It is respectfully requested that the Examiner consider the above-noted information and return an initialed copy of the attached Form PTO/SB/08A to the undersigned.

Dated: March 30, 2004

Respectfully submitted,
COOLEY GODWARD LLP

By: Sunil K. Singh
Sunil K. Singh
Reg. No. 45,298

Cooley Godward LLP
ATTN: Patent Group
Five Palo Alto Square
3000 El Camino Real
Palo Alto, CA 94306-2155
Tel: (650) 843-5000 Fax: (650) 857-0663
672761 v1/PA

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 5

Complete if Known	
Application Number	10/723,144
Filing Date	November 25, 2003
First Named Inventor	Amy L. ALLAN
Group Art Unit	1641
Examiner Name	Not yet assigned
Attorney Docket Number	ATTE-002/02US

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	U.S. Patent Document Number	Kind Code[2] (*if known*)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
	P1	6,472,369		Livant	10-29-2002
	P2	6,001,965		Livant	12-14-1999
	P3	5,994,309		Mazar *et al,*	07-25-1997
	P4	5,970,974		Van der Linden *et al.*	10-26-1999
	P5	5,954.047		Amer *et al,*	09-21-1999
	P6	5,950,619		van der Linden *et al.*	09-10-1997
	P7	5,698,155		Grosswald *et al.*	12-16-1997
	P8	5,639,725		O'Reilly *et al.*	06-17-1997
	P9	5,627,286		Ramalingam *et al.*	05-06-1997
	P10	5,618,513		Srinivasan	04-08-1997
	P11	5,567,408		Zamora	10-22-1996
	P12	5,561,220		Dean	10-01-1996
	P13	5,556,611		Biesalski	09-17-1996
	P14	5,443,816		Zamura *et al.*	08-22-1995
	P15	5,112,598		Biesalski	05-12-1992
	P16	4,765,539		Noakes *et al.*	08-23-1988
	P17	4,683,202		Mullis	07-28-1987
	P18	3,916,899		Theeuwes *et al.*	11-04-1975
	P19	3,845,770		Theeuwes *et al.*	11-05-1974

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Office[3]	Number[4]	Kind Code[5] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T[6]
	F1						
	F2						
	F3						

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number.
[2] See attached Kinds of U.S. Patent Documents.
[3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).
[4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.
[5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.
[6] Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 5

Complete if Known	
Application Number	10/723,144
Filing Date	November 25, 2003
First Named Inventor	Amy L. ALLAN
Group Art Unit	1614
Examiner Name	Not yet assigned
Attorney Docket Number	ATTE-002/02US

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	D1	ADELMAN *et al.*, "*In Vitro* Deletional Mutagenesis for Bacterial Production of the 20,000-Dalton Form of Human Pituitary Growth Hormone," *DNA* (1983), 2:183-193.	
	D2	ALDERMAN, "A Review of Cellulose Ethers in Hydrophilic Matrices for Oral Controlled-Release Dosage Forms," *Int. J. Pharm. Tech. & Prod. Mfr.* (1984), 5(3) 1-9.	
	D3	ALMQUIST *et al.*, "Synthesis and Biological Activity of a Ketomethylene Analogue of a Tripeptide Inhibitor of Angiotensin Converting Enzyme," *J. Med. Chem.* (1980), 23:1392	
	D4	BALDARI *et al.*, "A Novel Leader Peptide Which Allows Efficient Secretion of a Fragment of Human Interleukin 1β in *Saccharomyces* cerevisiae," EMBO *J.* (1987), 6:229-234	
	D5	BAMBA *et al.*, "Release Mechanisms in Gelforming Sustained Release Preparations," *Int. J. Pharm.* (1979), 2:307-315	
	D6	BEAUCAGE *et al.*, "Deoxynucleoside Phosphoramidites—A New Class of Key Intermediates for Deoxypolynucleotide Synthesis," *Tetrahedron Lett.* (1981), 22:1859	
	D7	BENJAMIN *et al.*, "Selective Ablation of Immature Blood Vessels in Established Human Tumors Follows Vascular Endothelial Growth Factor Withdrawal," *J. Clin. Invest.* (1999), 103:159-165	
	D8	BLOOD *et al.*, "Tumor Interactions with the Vasculature: Angiogenesis and Tumor Metastasis," *Biochim. Biophys. Acta* (1990), 1032:89-118	
	D9	BORGSTROM *et al.*, "Neutralizing Anti-Vascular Endothelial Growth Factor Antibody Completely Inhibits Angiogenesis and Growth of Human Prostate Carcinoma Micro Tumors In Vivo," *Prostate* (1998), 35:1-10	
	D10	BROOKS *et al.*, "Disruption of Angiogenesis by PEX, A Noncatalytic Metalloproteinase Fragment with Integrin Binding Activity," *Cell* (1998), 92:391-400	
	D11	BRUCHEZ *et al.*, "Semiconductor Nanocrystals as Fluorescent Biological Labels," *Science* (1998), 281:2013-2016	
	D12	CHAMBERS *et al.*, "Macrophage Colony-stimulating Factor Mediates Invasion of Ovarian Cancer Cells through Urokinase," *Canc. Res.* (1995), 55:1578-1585	
	D13	CHAN *et al*, "Quantum Dot Bioconjugates for Ultrasensitive Nonisotopic Detection," *Science* (1998), 281:2016-2018	
	D14	CHOREV *et al.*, "Partially Modified Retro-Inverso-Enkephalinamides: Topochemical Long-Acting Analogs in vitro and in vivo," *Science* (1979), 204:1210-1212	
	D15	CROWLEY *et al.*, "Prevention of Metastasis by Inhibition of the Urokinase Receptor," *Proc. Natl. Acad. Sci USA* (1993), 90:5021-5025	
	D16	DURING *et al.*, "Controlled Release of dopamine from a Polymeric Brain Implant: In Vivo Characterization," *Ann. Neurol.* (1989) 25:351	
	D17	EDGE, "Total Synthesis of a Human Leukocyte Interferon Gene," *Nature* (1981), 292:756-762	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	D18	FOLKMAN, "Anti-Angiogenesis: New Concept for Therapy of Solid Tumors," *Ann. Surg.* (1972), 175:409-416	
	D19	FOLKMAN, "The Influence of Angiogenesis Research on Management of Patients with Breast Cancer," *Breast Cancer Res. Treat.* (1995), 36(2):109-118	
	D20	FOLKMAN, "Angiogenesis Inhibitors Generated by Tumors," *Mol. Med.* (1995), 1(2):120-122;	
	D21	GIANNIS *et al.*, "Peptidomimetics in Drug Design," *Adv. In Drug Res.* (1997), 29:1-78	
	D22	GLUZMAN, "SV40-Transformed Simian Cells Support the Replication of Early SV40 Mutants," *Cell* (1981), 23:175-182	
	D23	GOODSON, "Medical Application of Controlled Release" 2:115-138 (1984)	
	D24	GORELIK *et al.*, "Control of Lung Metastasis Progression in Mice: Role of Growth Kinetics of 3LL Lewis Lung Carcinoma and Host Immune Reactivity," *J. Nat'l Canc. Inst.*, (1980), 65:1257-1264	
	D25	GORELIK *et al.*, "Host's Immune State and Kinetics of Local Tumor Growth Control – Progression of Postoperative Lung Metastasis," *Rec. Results Canc. Res.* (1980), 75:20-28	
	D26	HANAHAN *et al.*, "Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis," *Cell* (1996), 86(3):353-364	
	D27	HILGARD *et al.*, "Oral Anticoagulation in the Treatment of a Spontaneously Metastasising Murine Tumour (3LL)," *Br. J. Cancer* (1977), 35:78-86	
	D28	HOLLADAY *et al.*, "Synthesis of Hydroxyethlene and Ketomethylene Dipeptide Isosteres," *Tetrahedron Lett.* (1983), 24:4401-4404	
	D29	HOWARD *et al.*, "Intracerebral drug delivery in rats with lesion-induced memory deficits," *J. Neurosurg.* (1989), 71:105-112	
	D30	HRUBY, "Conformational Restrictions of Biologically Active Peptides Via Amino Acid Side Chain Groups," *Life Sci.* (1982), 4:189-199	
	D31	HRUBY, "Conformational and Topographical Considerations in the Design of Biologically Active Peptides," *Biopolymers* (1993), 33:1073-1082	
	D32	ISAKOV *et al.*, "An Immune Response against the Alloantigens of the 3LL Lewis Lung Carcinoma Prevents the Growth of Lung Metastases, but Not of Local Allografts," *Invasion Matas.* (1982) 2:12-32	
	D33	JAY, "Chemical Synthesis of a Biologically Active Gene for Human Immune Interferon-γ," *J. Biol. Chem* (1984), 259:6311-6317	
	D34	JENNING-WHITE *et al.*, "Synthesis of Ketomethylene Analogs of Dipeptides," *Tetrahedron Lett.* (1982), 23:2533-2534	
	D35	KAUFMAN *et al.*, "Translational Efficiency of Polycistronic mRNAs and their Utilization to Express Heterologous Genes in Mammalian cells," *EMBO J.*, (1987), 6:187-195	
	D36	KLEINMAN *et al.*, "Basement Membrane Complexes with Biological Activity," *Biochemistry* (1986), 25:312-318	
	D37	KURJAN *et al.*, "Structure of a Yeast Pheromone Gene (MFα): A Putative α-Factor Precursor Contains Four Tandem Copies of Mature α-Factor," *Cell*, (1982), 30:933-943	
	D38	LANGER *et al.*, "Chemical and Physical Structure of Polymers as Carriers for Controlled Release of Bioactive Agents: A Review," *J. Macromol. Sci. Rev. Macromol Chem.*, (1983), 23:61	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	D39	LANGER, "New Methods of Drug Delivery," *Science*, (1990), 249:1527-1533	
	D40	LEVY *et al.*, "Inhibition of Calcification of Bioprosthetic Heart Valves by Local Controlled-Release Diphosphonate," *Science*, (1985) 228:190	
	D41	LUCKLOW *et al.*, "High Level Expression of Nonfused Foreign Genes with *Autographa californica* Nuclear Polyhedrosis Virus Expression Vectors," Virology (1989), 170:31-39	
	D42	MALAVE *et al.*, "Influence of Inoculation Site on Development of the Lewis Lung Carcinoma and Suppressor Cell Activity in Syngeneic Mice," *J. Nat'l. Canc. Inst.* (1979), 62:83-88	
	D43	MATTEUCCI *et al.*, "Synthesis of Deoxyoligonucleotides on a Polymer Support," *J. Am. Chem Soc.* (1981), 103:3185	
	D44	MAXAM *et al.*, "Nucleic Acids," *Meth. Enzymol.* (1980), 65:499-560	
	D45	MERRIFIELD, "Solid Phase Peptide Synthesis. I. "The Synthesis of a Tetrapeptide," *J. Amer. Chem. Soc.* (1963), 85:2149-54	
	D46	MESSING *et al.*, "A System for Shotgun DNA Sequencing," *Nucleic Acids Res.* (1981), 9:309	
	D47	MILLAUER *et al.*, "Dominant-Negative Inhibition of Flk-1 Suppresses the Growth of Many Tumor Types *in* Vivo," Cancer *Res.* (1996), 56:1615-1620	
	D48	MIN *et al.*, "Urokinase Receptor Antagonists Inhibit Angiogenesis and Primary Tumor Growth in Syngeneic Mice," *Cancer Res.* (1996), 56:2428-2433	
	D49	MOORE *et al.*, "Design and Pharmacology of Peptide Mimetics," *Adv. In Pharmacol.* (1995), 33:91-141	
	D50	NAMBAIR *et al.*, "Total Synthesis and Cloning of a Gene Coding for the Ribonuclease S Protein," *Science* (1984), 223:1299-1301	
	D51	NGUYEN *et al.*, "Quantitation of Angiogenesis and Antiangiogenesis in the Chick Embryo Chorioallantoic Membrane," *Microvascular Res.* (1994), 47:31-40	
	D52	ODEDRA *et al.*, "Low Molecular Weight Angiogenesis Factors," *Pharmac. Ther. (1991), 49:111-124*	
	D53	OLSON *et al.*, "Concepts and Progress in the Development of Peptide Mimetics," *J. Med. Chem.* (1993), 36:3039	
	D54	O'REILLY *et al.*, "Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth," *Cell* (1997), 88:277-285	
	D55	O'REILLY *et al.*, "Angiostatin: A Novel Angiogenesis Inhibitor That Mediates the Suppression of Metastases by a Lewis Lung Carcinoma," *Cell* (1994), 79:315-328	
	D56	PARISH *et al.*, (1992), "A Basement-Membrane Permeability Assay Which Correlates With The Metastatic Potential of Tumour Cells," *Int. J. Cancer* 52:378-383	
	D57	PASSANITI *et al.*, "A Simple, Quantitative Method for Assessing Angiogenesis and Antiangiogenic Agents Using Reconstructed Basement Membrane, Heparin, and Fibroblast Growth Factor," *Lab Invest.* (1992), 67:519-528	
	D58	RABBANI *et al.*, "Prevention of Prostate-Cancer Metastasis *In Vivo* by a Novel Synthetic Inhibitor of Urokinase-Type Plasminogen Activator (uPA)" *Int. J. Cancer* (1995), 63:840-845	
	D59	SANGER, "DNA sequencing with chain-terminating inhibitors," *Proc. Natl. Acad. Sci. USA* (1977), 74:5463-5467	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	D60	SAUDEK *et al.*, "A Preliminary Trial of the Programmable Implantable Medication System for Insulin Delivery," *N. Engl. J. Med.* (1989), 321:574	
	D61	SCHNAPER *et al.*, "Plasminogen Activators Augment Endothelial Cell Organization In Vitro by Two Distinct Pathways," *J. Cell. Physiol.* (1995), 165:107-118	
	D62	SCHOCKLEY *et al.*, "Penetration of Tumor Tissue by Antibodies and Other Immunoproteins," *Ann. N.Y. Acad. Sci.* (1991), 617:367-382	
	D63	SCHULTZ *et al.*, "Expression and secretion in yeast of a 400-kDa envelope glycoprotein derived from Epstein—Barr virus," *Gene,* (1987),54:113-123	
	D64	SEFTON, "Implantable Pumps," *CRC Crit. Ref. Biomed. Eng.* (1987), 14:201	
	D65	SMITH *et al.*, "Production of Human Beta Interferon in Insect Cells Infected with a Baculovirus Expression Vector," *Mol. Cell Biol.* (1983), 3:2156-2165	
	D66	SPATOLA, "Chemistry and Biochemistry of Amino Acids, Peptides and Proteins," B. Weinstein, (eds.), *Marcel Dekker, New York,* (1983) 267-357	
	D67	SPATOLA *et al.*, "Structure-Activity Relationships of Enkephalins Containing Serially Replaced Thiomethylene Amide Bond Surrogates," *Life Sci.* (1986), 38:1243-1249	
	D68	TALMADGE *et al.*, "Enhanced Metastatic Potential of Tumor Cells Harvested From Spontaneous Metastases of Heterogeneous Murine Tumors," *J. Nat'l. Canc. Inst.* (1982), 69:975-980	
	D69	THAKUR *et al.*, "Indium-111-labeled leukocytes for the localization of abscesses: preparation, analysis, tissue distribution, and comparison with gallium-67 citrate in dogs," *J. Lab. Clin. Med.* (1977), 89:217-228	
	D70	TREAT *et al.*, "Liposomes in the Therapy of Infectious Diseases and Cancer", *Lopez-Berestein and Fidler* (eds.), *Liss, New York,* pp. 353-365 (1989)	
	D71	VERMA *et al.*, "Osmotically Controlled Oral Drug Delivery," *Drug Dev. Ind. Pharm.* (2000), 26:695-708	
	D72	VERSCHOYLE *et al.*, "Pharmacokinetics of Isotretinoin (ISO) in Rats following Oral Dosing or Aerosol Inhalation," *British J. Cancer* (1999), 80 Suppl. 2, 96	
	D73	VOLPERT *et al.*, "Captopril Inhibits Angiogenesis and Slows the Growth of Experimental Tumors in Rats," *J. Clin. Invest.* (1996), 98:671-679	
	D74	WILEY *et al.*, "Peptidomimetics Derived from Natural Products," *Med Res. Rev.* (1993), 13:327-384	
	D75	XING *et al.*, "Overexpression of Urokinase Receptor in Breast Cancel Cells Results In Increased Tumor Invasion, Growth and Metastasis," *Int. J. Cancer* (1996), 67:423-429	
	D76	ZOLLER *et al.*, "Oligonucleotide-directed mutagenesis using M13-derived vectors: an efficient and general procedure for the production of point mutations in any fragment of DNA," *Nucleic Acids Res.* (1982), 10:6487-6500	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

672602 v1/PA

[1] Unique citation designation number.

[2] Applicant is to place a check mark here if English language Translation attached.